The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Suchkov I.A.
Ryazan State Medical University
Mzhavanadze N.D.
Ryazan State Medical University
The Effect of Standardized Doses of Hesperidin and Diosmin on Venous Wall Remodeling in Patients with Primary Varicose Veins: a Prospective Controlled Study “STANDARD”
Journal: Journal of Venous Disorders. 2024;18(4): 293‑301
Views: 357
Downloaded: 6
To cite this article:
Suchkov IA, Mzhavanadze ND, Kalinin RE, et al. . The Effect of Standardized Doses of Hesperidin and Diosmin on Venous Wall Remodeling in Patients with Primary Varicose Veins: a Prospective Controlled Study “STANDARD”. Journal of Venous Disorders.
2024;18(4):293‑301. (In Russ.)
https://doi.org/10.17116/flebo202418041293
O study the effect of fixed doses combination of hesperidin and diosmin on venous wall remodeling in patients with primary varicose veins after therapy and endovenous laser ablation (EVLA).
A single-center parallel-group prospective controlled study (ClinicalTrials.gov ID: NCT06367166) included 83 patients with varicose veins C2—C3 and 20 healthy volunteers (83 women and 20 men). Subjects were divided depending on treatment strategy: group A — 20 patients received hesperidin (100 mg) and diosmin (900 mg) once a day for 6 months; group B — 20 patients without therapy and invasive treatment; group C — 21 patients received hesperidin (100 mg) and diosmin (900 mg) once a day for 6 months after EVLA; group D — 22 patients underwent EVLA; group E — 20 healthy volunteers. Compression stockings class 2 were prescribed in groups A, B, C and D. We assessed vascular wall remodeling markers using ELISA: von Willebrand factor (vWF), PECAM-1 (CD31), fibronectin (FN), vimentin (VIM), plasminogen activation inhibitor type 1 (PAI-1). Additionally, we studied severity of symptoms using VAS and VCSS scales, as well as quality of life using CIVIQ-20 questionnaire.
After 6-month therapy with fixed doses combination of bioflavonoids: hesperidin 100 mg and diosmin 900 mg (VENARUS), we observed more than 6-fold decrease in PAI-1 (p<0.001), more than 22-fold decrease in FN (p<0.001), 2-fold decrease in VIM (p=0.042), 3-fold decrease in vWF (p=0.001) and 1.5-fold decrease in PECAM-1 (p<0.001). EVLA combined with fixed doses combination of bioflavonoids was characterized by more than 9.5-fold decrease in serum PAI-1 (p<0.001), 4.5-fold decrease in FN (p<0.001), 2.5-fold decrease in VIM (p<0.001), 1.8-fold decrease in vWF (p=0.008) and 25% decrease in PECAM-1 (p<0.001) after 6-month therapy. Similar changes were not observed in other groups. The best results regarding severity of symptoms and quality of life were observed after EVLA including postoperative therapy with fixed doses combinations of bioflavonoids.
Fixed doses combination of bioflavonoids (hesperidin 100 mg and diosmin 900 mg) contribute to significant changes of venous wall remodeling markers, relief of symptoms and QoL improvement in patients with varicose veins.
Keywords:
Authors:
Suchkov I.A.
Ryazan State Medical University
Mzhavanadze N.D.
Ryazan State Medical University
Received:
07.09.2024
Accepted:
11.09.2024
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.